FOLH1 and prostate cancer: In presumed localized high risk prostate cancer, PSMA PET/CT has also prospectively demonstrated improved sensitivity and specificity compared to conventional imaging with a higher detection rate of nodal and metastatic lesions thereby resulting in significant treatment management change [5].